ArticleThe EPMA journal2011
Application of proteomics for the identification of biomarkers in amniotic fluid: are we ready to provide a reliable prediction?
Article in The EPMA journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Profiling Cytokines According to the Presence or Absence of Small-for-Gestational Age Using Amniotic Fluid Retrieved During Cesarean Section From Pregnant Women With Early-Onset Preeclampsia.Journal of Korean medical science · 2025Article
- Identification of Neurocan and Phosphacan as Early Biomarkers for Open Neural Tube Defects.Cells · 2023Article
- The amniotic fluid proteome predicts imminent preterm delivery in asymptomatic women with a short cervix.Scientific reports · 2022Article
- Identification of differentially expressed genes in salt-tolerant oilseed sunflower (Helianthus annuus L.) genotype by RNA sequencing.Molecular biology reports · 2022Article
- The amniotic fluid proteome changes with gestational age in normal pregnancy: a cross-sectional study.Scientific reports · 2022Article
- IgGFc-binding protein in pregnancies complicated by spontaneous preterm delivery: a retrospective cohort study.Scientific reports · 2021Article
- Article
- iTRAQ and PRM-based quantitative proteomics in early recurrent spontaneous abortion: biomarkers discovery.Clinical proteomics · 2019Article
- Serum biomarker analysis in patients with recurrent spontaneous abortion.Molecular medicine reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteomics-based identification of biomarkers for fetal abnormalities and pregnancy complications in amniotic fluid (AF) has made significant progress in the past 5 years. This is attributed mainly to advances in mass spectrometry-based proteomic technologies that enable new strategies for discovering biomarkers from complex biological fluids in a high-throughput and sensitive manner. These markers, although they still need to be verified, are diagnostic and may in the future provide targets for therapeutic intervention. In the current review we focus on the emergence of proteomics as a major platform technology in studying AF and developing biomarkers for fetal aneuploidies and pregnancy-related disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.